Last reviewed · How we verify
Thromboprophylaxis
Thromboprophylaxis is a Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 3 development.
Thromboprophylaxis is medical treatment to prevent the development of thrombosis in individuals at risk, such as those with cancer undergoing surgery. Interventions for thromboprophylaxis include electronic health record alerts, like the one used in the "eVTE" study, to prompt providers to prescribe medications like rivaroxaban to reduce the risk of venous thromboembolism.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Thromboprophylaxis |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion (NA)
- GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis (NA)
- The Intensive Care Platform Trial (PHASE4)
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (PHASE3)
- Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
- Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement (NA)
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thromboprophylaxis CI brief — competitive landscape report
- Thromboprophylaxis updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI
Frequently asked questions about Thromboprophylaxis
What is Thromboprophylaxis?
Who makes Thromboprophylaxis?
What development phase is Thromboprophylaxis in?
Related
- Manufacturer: Gustave Roussy, Cancer Campus, Grand Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing